Strategic M&A Pulmatrix merged with Eos SENOLYTIX, creating a broader platform and potential cross-sell opportunities for respiratory and non-respiratory therapies through iSPERSE delivery.

Financing Momentum Recent Series B financing and private placement tied to the merger suggest strong investor confidence and potential for co-development deals or financing partnerships for late-stage trials.

Pipeline Potential Active development programs including PUR3100 and PUR1800 indicate multiple inhaled NSKI assets with iSPERSE delivery, presenting opportunities for co-development, licensing, or manufacturing partnerships.

Clinical Evidence Multiple Phase 1/Phase Ib results and publications on inhaled therapies provide validation for collaboration with sponsors seeking evidence-based inhaled solutions and DDI profiling.

Global Reach Framingham base with world-facing press and public disclosures, plus a focus on global commercialization through iSPERSE, open doors for distribution partnerships, regional licensing, and manufacturing arrangements.